The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio. Nonetheless, Moderna has previously been involved in licensing deals to advance its technology.
